ArticleHuman genomics2025
Prioritizing missense mutations via a deep learning phosphorylation prediction model.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPhosphorylation is a crucial post-translational modification mechanism that enhances proteomic diversity, and its malfunction has been confirmed to be associated with complex traits, especially brain disorders. One of the factors contributing to this malfunction is the missense mutations given that they may alter the peptides flanking the phosphorylated residues. However, the specific effects of these missense mutations on phosphorylation remain unclear.
methodsTo ascertain these, a deep learning phosphorylation prediction model (DeepMEP), which is the first to be developed on a Chinese-brain-specific phosphorylation dataset (CBMAP), was established to bridge the phosphorylation and peptides. The impact of each missense mutation on phosphorylation was subsequently quantified based on the differences between the outputs of reference and mutant protein sequences. A permutation test adjusting for the confounding factors was finally employed to estimate the enrichment for high-impact mutations in disease-associated genomic loci.
resultsDeepMEP achieved superior predictive performance compared with other existing tools on both CBMAP and publicly available datasets. Enrichment analysis revealed the high-impact mutations were significantly enriched in GWAS signals for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The corresponding genes of those missense mutations overlapping with GWAS included ABCA7, APOE, and PLCG2 for AD, and MMRN1 and TMEM175 for PD, which are disease-associated genes confirmed by other studies beyond GWAS.
conclusionOur study demonstrated that DeepMEP effectively captured the impact of missense mutations on phosphorylation and highlighted an enrichment of high-impact mutations in AD- and PD-associated genomic loci.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.